Literature DB >> 23231879

Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists.

S G Parameswaran, C Chang, A K Swenson, M Shumway, M Olfson, C V Mangurian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23231879      PMCID： PMC3823536          DOI： 10.1016/j.schres.2012.08.031

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  9 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

Authors:  Peter F Buckley; Del D Miller; Beth Singer; John Arena; Edna M Stirewalt
Journal:  Schizophr Res       Date:  2005-06-20       Impact factor: 4.939

3.  Psychiatric opinion and antipsychotic selection in the management of schizophrenia.

Authors:  Melissa R Arbuckle; Marc J Gameroff; Steven C Marcus; Joyce C West; Joshua Wilk; Mark Olfson
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

4.  Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

Authors:  Henry A Nasrallah; Jonathan M Meyer; Donald C Goff; Joseph P McEvoy; Sonia M Davis; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2006-08-01       Impact factor: 4.939

5.  Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia.

Authors:  Mark Olfson; Steven C Marcus; Joshua Wilk; Joyce C West
Journal:  Psychiatr Serv       Date:  2006-02       Impact factor: 3.084

6.  The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.

Authors:  John W Newcomer; Henry A Nasrallah; Antony D Loebel
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

7.  Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Authors:  Elaine H Morrato; Benjamin Druss; Daniel M Hartung; Robert J Valuck; Richard Allen; Elizabeth Campagna; John W Newcomer
Journal:  Arch Gen Psychiatry       Date:  2010-01

8.  Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

Authors:  Gail L Daumit; Donald C Goff; Jonathan M Meyer; Vicki G Davis; Henry A Nasrallah; Joseph P McEvoy; Robert Rosenheck; Sonia M Davis; John K Hsiao; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2008-09-04       Impact factor: 4.939

9.  Adding or switching antipsychotic medications in treatment-refractory schizophrenia.

Authors:  Julie Kreyenbuhl; Steven C Marcus; Joyce C West; Joshua Wilk; Mark Olfson
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084
  9 in total
  9 in total

1.  Opinions of Primary Care Clinicians and Psychiatrists on Monitoring the Metabolic Effects of Antipsychotics.

Authors:  Christina Mangurian; Aishat Giwa; Erin Brosey; Martha Shumway; James Dilley; Elena Fuentes-Afflick; Eliseo J Pérez-Stable; Dean Schillinger
Journal:  J Am Board Fam Med       Date:  2019 May-Jun       Impact factor: 2.657

Review 2.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

3.  A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists.

Authors:  Christina Mangurian; Chelsea Modlin; Lindsey Williams; Susan Essock; Nicholas S Riano; Martha Shumway; John W Newcomer; James W Dilley; Dean Schillinger
Journal:  Community Ment Health J       Date:  2017-11-28

4.  Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study.

Authors:  Christina Mangurian; Dean Schillinger; John W Newcomer; Eric Vittinghoff; Susan Essock; Zheng Zhu; Wendy Dyer; Julie Schmittdiel
Journal:  J Gen Intern Med       Date:  2017-10-31       Impact factor: 5.128

Review 5.  Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.

Authors:  Christina Mangurian; John W Newcomer; Chelsea Modlin; Dean Schillinger
Journal:  J Gen Intern Med       Date:  2016-05-05       Impact factor: 5.128

6.  Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication.

Authors:  Christina Mangurian; Funmi Giwa; Martha Shumway; Elena Fuentes-Afflick; Eliseo J Pérez-Stable; James W Dilley; Dean Schillinger
Journal:  Psychiatr Serv       Date:  2013-06       Impact factor: 3.084

7.  Monitoring of Adverse Drug Reaction-Related Parameters in Children and Adolescents Treated With Antipsychotic Drugs in Psychiatric Outpatient Clinics.

Authors:  Lenneke Minjon; Ivona Brozina; Toine C G Egberts; Eibert R Heerdink; Els van den Ban
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

8.  Psychiatrists' follow-up of identified metabolic risk: a mixed-method analysis of outcomes and influences on practice.

Authors:  Sue Patterson; Kathleen Freshwater; Nicole Goulter; Julie Ewing; Boyd Leamon; Anand Choudhary; Vikas Moudgil; Brett Emmerson
Journal:  BJPsych Bull       Date:  2016-10

9.  Association of cardiovascular metabolic risk factor measurements with psychiatric readmission among in-hospital patients with severe mental illness: a retrospective study.

Authors:  Xiao Wei Tan; Christopher Yi Wen Chan; Alvin Wai Mum Lum; Eng Sing Lee; Yee Ming Mok; Daniel Shuen Sheng Fung; Phern Chern Tor
Journal:  BMC Psychiatry       Date:  2022-01-18       Impact factor: 3.630
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.